A leading RNAi therapeutics company.
In nonhuman primates, ALN-TTRsc administration led to an approximately 80 percent reduction of TTR at doses only 2.5 mg/kg. In single – and multi-dosage pre-clinical safety research in rodents and nonhuman primates, ALN-TTRsc was found to be safe and well tolerated generally. Specifically, at dosages as high as 300 mg/kg in nonhuman primates, ALN-TTRsc was well tolerated with no clinical signs, no adverse laboratory or histopathologic findings, no elevations in complement or cytokines, and no significant injection site reactions. Alnylam entered into an exclusive alliance with Genzyme, a Sanofi firm, to develop and commercialize RNAi therapeutics, including ALN-TTR02 and ALN-TTRsc, for the treatment of ATTR in Japan and the broader Asian-Pacific region.Putting huge servings farther back upon shelves, wrapping person portions or indicating single-serving sizes may also help curb overeating visually, the study suggested. The experts also recommend restricting bargain pricing of fattening foods sold in larger portions or bulk sizes. But how much such steps can help in the long-term remains to be seen, as the analysis doesn’t prove that downsizing portions and deals will translate to slimmer people. With the notable exception of directly controlling the sizes of the foods people consume, dependable evidence regarding the efficiency of specific actions to lessen the size, availability or selling point of larger-sized food portions is currently lacking and urgently required, said Hollands.